Show simple item record

dc.contributor.authorRamírez Carracedo, Rafael
dc.contributor.authorSanmartin, Marcelo
dc.contributor.authorTen, Amadeo
dc.contributor.authorHernandez, Ignacio
dc.contributor.authorTesoro Santos, Laura 
dc.contributor.authorDiez-Mata, Javier
dc.contributor.authorBotana, Laura
dc.contributor.authorOvejero-Paredes, Karina
dc.contributor.authorFilice, Marco
dc.contributor.authorAlberich-Bayarri, Angel
dc.contributor.authorMartí-Bonmatí, Luis
dc.contributor.authorLargo-Aramburu, Carlota
dc.contributor.authorSaura, Marta
dc.contributor.authorZamorano, Jose Luis
dc.contributor.authorZaragoza Sánchez, Carlos
dc.description.abstractBACKGROUND: Rapid screening and accurate diagnosis of acute myocardial infarction are critical to reduce the progression of myocardial necrosis, in which proteolytic degradation of myocardial extracellular matrix plays a major role. In previous studies, we found that targeting the extracellular matrix metalloprotease inducer (EMMPRIN) by injecting nanoparticles conjugated with the specific EMMPRIN-binding peptide AP9 significantly improved cardiac function in mice subjected to ischemia/reperfusion. METHODS: In a porcine model of coronary ischemia/reperfusion, we tested the theragnostic effects of administering 0.1 mg/kg gadolinium-containing nanoparticles conjugated with AP9 (NAP9), a synthetic peptide that targets EMMPRIN or a control nanoparticle (NAPSC). Cardiac magnetic resonance assessment of the infarct progression, ventricular function, and nanoparticle distribution was performed the next 7 days. We also measured the infarcted area of the heart and cardiac remodeling at 7 or 21 days after ischemia/reperfusion. RESULTS: After 21 days of ischemia/reperfusion, NAP9 reduced the extension of cardiac necrosis (14.1±9.7 versus 35.5±1.8) and the levels of collagenolytic activity of MMPs (matrix metalloproteases), along with a significant reduction in collagen deposition (7.5±4.5 versus 41.3±20); including the ratio of type I versus III collagen fibers in the necrotic myocardium. In terms of cardiac function, the response to NAP9 administration resulted in a significant improvement of cardiac performance overtime, as evidenced by the left ventricle ejection fraction (64.0±7.8), when compared with those present in the NAPSC group (47.3±4.7). As shown by magnetic resonance imaging, noninvasive molecular imaging of NAP9 enabled us to find a significant reduction in cardiac necrosis, myocardial edema, hemorrhage, and microvascular obstruction, suggesting that NAP9 may reduce myocardial injury and preserve left ventricular function, at least, by preventing the effect of EMMPRIN on extracellular matrix degradation. CONCLUSIONS: Our data point towards NAP9 as a promising theragnostic tool in managing acute myocardial infarction, by inhibiting EMMPRIN-induced extracellular matrix degradation and allowing noninvasive visualization of cardiac necrosis progression over
dc.publisherCirculation: cardiovascular imagingspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectExtracellular matrixspa
dc.subjectMyocardial infarctionspa
dc.titleTheranostic Contribution of Extracellular Matrix Metalloprotease Inducer-Paramagnetic Nanoparticles Against Acute Myocardial Infarction in a Pig Model of Coronary Ischemia-
dc.typejournal articlespa
dc.rights.accessRightsopen accessspa
dc.description.extent2535 KBspa

Files in this item

2.- Theranostic Contribution of ...2.474MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España